• We are sorry, but NCBI web applications do not support your browser and may not function properly. More information
Logo of jcinvestThe Journal of Clinical InvestigationCurrent IssueArchiveSubscriptionAbout the Journal
J Clin Invest. Mar 15, 1998; 101(6): 1325–1333.
PMCID: PMC508687

Involvement of nitric oxide system in experimental muscle crush injury.


Muscle crush injury is often complicated by hemodynamic shock, electrolyte disorders, and myoglobinuric renal failure. In this study, we examined the involvement of the nitric oxide (NO) system in the development of muscle damage in an experimental model of crush injury induced by exertion of standardized mechanical pressure on tibialis muscle of rat. The intact limb served as a control. Four days after injury, the crushed muscle was characterized by extreme capillary vasodilatation as demonstrated by histological morphometric analysis. These changes were accompanied by muscle hyperperfusion as evaluated by measurements of femoral blood flow (ultrasonic flowmetry) and capillary blood flow (laser-doppler flowmetry). Treatment with Nomega-nitro-L-arginine methyl ester, a NO synthase (NOS) inhibitor, largely decreased the hyperperfusion. Furthermore, the expression of the different NOS isoforms, assessed by reverse transcription-PCR and immunoreactive levels, determined by Western blot, revealed a remarkable induction of the inducible NOS in the crushed limb. Similarly, endothelial NOS mRNA increased gradually after the induction of muscle damage. In contrast, the major muscular NOS, i.e., neuronal isoform remained unchanged. In line with the alterations in the mRNA levels, Western blot analysis revealed parallel changes in the immunoreactive levels of the various NOS. These findings indicate that muscle crush is associated with activation of the NO system mainly due to enhancement of iNOS. This may contribute to NO-dependent extreme vasodilatation in the injured muscle and aggravate the hypovolemic shock after crush injury.

Full Text

The Full Text of this article is available as a PDF (516K).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.
  • Bywaters EG. 50 years on: the crush syndrome. BMJ. 1990 Dec 22;301(6766):1412–1415. [PMC free article] [PubMed]
  • Better OS, Rubinstein I, Winaver J. Recent insights into the pathogenesis and early management of the crush syndrome. Semin Nephrol. 1992 Mar;12(2):217–222. [PubMed]
  • Better OS, Stein JH. Early management of shock and prophylaxis of acute renal failure in traumatic rhabdomyolysis. N Engl J Med. 1990 Mar 22;322(12):825–829. [PubMed]
  • Better OS, Abassi Z, Rubinstein I, Marom S, Winaver Y, Silberman M. The mechanism of muscle injury in the crush syndrome: ischemic versus pressure-stretch myopathy. Miner Electrolyte Metab. 1990;16(4):181–184. [PubMed]
  • Kobzik L, Reid MB, Bredt DS, Stamler JS. Nitric oxide in skeletal muscle. Nature. 1994 Dec 8;372(6506):546–548. [PubMed]
  • Kobzik L, Stringer B, Balligand JL, Reid MB, Stamler JS. Endothelial type nitric oxide synthase in skeletal muscle fibers: mitochondrial relationships. Biochem Biophys Res Commun. 1995 Jun 15;211(2):375–381. [PubMed]
  • Moncada S, Higgs A. The L-arginine-nitric oxide pathway. N Engl J Med. 1993 Dec 30;329(27):2002–2012. [PubMed]
  • Moncada S, Higgs EA. Endogenous nitric oxide: physiology, pathology and clinical relevance. Eur J Clin Invest. 1991 Aug;21(4):361–374. [PubMed]
  • Frandsen U, Lopez-Figueroa M, Hellsten Y. Localization of nitric oxide synthase in human skeletal muscle. Biochem Biophys Res Commun. 1996 Oct 3;227(1):88–93. [PubMed]
  • Bates TE, Loesch A, Burnstock G, Clark JB. Mitochondrial nitric oxide synthase: a ubiquitous regulator of oxidative phosphorylation? Biochem Biophys Res Commun. 1996 Jan 5;218(1):40–44. [PubMed]
  • Thompson M, Becker L, Bryant D, Williams G, Levin D, Margraf L, Giroir BP. Expression of the inducible nitric oxide synthase gene in diaphragm and skeletal muscle. J Appl Physiol (1985) 1996 Dec;81(6):2415–2420. [PubMed]
  • Brenman JE, Chao DS, Xia H, Aldape K, Bredt DS. Nitric oxide synthase complexed with dystrophin and absent from skeletal muscle sarcolemma in Duchenne muscular dystrophy. Cell. 1995 Sep 8;82(5):743–752. [PubMed]
  • Anggård E. Nitric oxide: mediator, murderer, and medicine. Lancet. 1994 May 14;343(8907):1199–1206. [PubMed]
  • Peterson DA, Peterson DC, Archer S, Weir EK. The non specificity of specific nitric oxide synthase inhibitors. Biochem Biophys Res Commun. 1992 Sep 16;187(2):797–801. [PubMed]
  • Plyley MJ, Groom AC. Geometrical distribution of capillaries in mammalian striated muscle. Am J Physiol. 1975 May;228(5):1376–1383. [PubMed]
  • Chomczynski P, Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem. 1987 Apr;162(1):156–159. [PubMed]
  • Tso JY, Sun XH, Kao TH, Reece KS, Wu R. Isolation and characterization of rat and human glyceraldehyde-3-phosphate dehydrogenase cDNAs: genomic complexity and molecular evolution of the gene. Nucleic Acids Res. 1985 Apr 11;13(7):2485–2502. [PMC free article] [PubMed]
  • Har-Shai Y, Silbermann M, Reis ND, Zinman C, Rubinstein I, Abassi Z, Better OS. Muscle microcirculatory impairment following acute compartment syndrome in the dog. Plast Reconstr Surg. 1992 Feb;89(2):283–289. [PubMed]
  • Kubes P. Nitric oxide-induced microvascular permeability alterations: a regulatory role for cGMP. Am J Physiol. 1993 Dec;265(6 Pt 2):H1909–H1915. [PubMed]
  • Reid MB, Khawli FA, Moody MR. Reactive oxygen in skeletal muscle. III. Contractility of unfatigued muscle. J Appl Physiol (1985) 1993 Sep;75(3):1081–1087. [PubMed]
  • Moncada S, Higgs EA. Molecular mechanisms and therapeutic strategies related to nitric oxide. FASEB J. 1995 Oct;9(13):1319–1330. [PubMed]
  • Cleeter MW, Cooper JM, Darley-Usmar VM, Moncada S, Schapira AH. Reversible inhibition of cytochrome c oxidase, the terminal enzyme of the mitochondrial respiratory chain, by nitric oxide. Implications for neurodegenerative diseases. FEBS Lett. 1994 May 23;345(1):50–54. [PubMed]
  • Heppenstall RB, Scott R, Sapega A, Park YS, Chance B. A comparative study of the tolerance of skeletal muscle to ischemia. Tourniquet application compared with acute compartment syndrome. J Bone Joint Surg Am. 1986 Jul;68(6):820–828. [PubMed]
  • de Vera ME, Shapiro RA, Nussler AK, Mudgett JS, Simmons RL, Morris SM, Jr, Billiar TR, Geller DA. Transcriptional regulation of human inducible nitric oxide synthase (NOS2) gene by cytokines: initial analysis of the human NOS2 promoter. Proc Natl Acad Sci U S A. 1996 Feb 6;93(3):1054–1059. [PMC free article] [PubMed]
  • Noiri E, Peresleni T, Miller F, Goligorsky MS. In vivo targeting of inducible NO synthase with oligodeoxynucleotides protects rat kidney against ischemia. J Clin Invest. 1996 May 15;97(10):2377–2383. [PMC free article] [PubMed]
  • Zager RA. Rhabdomyolysis and myohemoglobinuric acute renal failure. Kidney Int. 1996 Feb;49(2):314–326. [PubMed]

Articles from The Journal of Clinical Investigation are provided here courtesy of American Society for Clinical Investigation


Related citations in PubMed

See reviews...See all...

Cited by other articles in PMC

See all...


  • Compound
    PubChem Compound links
  • MedGen
    Related information in MedGen
  • PubMed
    PubMed citations for these articles
  • Substance
    PubChem Substance links

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...